MedTrace Logo

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

NCT06445322 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-03-11

No results posted yet for this study

Summary

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Conditions

  • Stargardt Disease
  • Stargardt Disease 1
  • Cone Rod Dystrophy
  • Juvenile Macular Degeneration

Interventions

DIAGNOSTIC_TEST

Prescreening Assessments

Various genetic and visual assessments.

Sponsors & Collaborators

  • Ascidian Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Alia Rashid · Ascidian Therapeutics

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-20
Primary Completion
2027-08-31
Completion
2030-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06445322 on ClinicalTrials.gov